QDEL stock sentiment todayQuidelOrtho Corp
Sentiment verdict
Gossip first, financials second — COLD at 85% confidence.
Last updated · cached analysis, refreshes periodically
QDEL
QuidelOrtho CorpA victim of the post-pandemic diagnostic hangover, QDEL is struggling with massive debt from the Ortho merger and collapsing COVID-related revenues.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for QDEL. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the 'cliff' effect as COVID-19 testing revenue evaporates, leaving the company with a bloated cost structure. Investors are frustrated by the recent CEO transition and a lack of clear guidance on how the integrated QuidelOrtho entity will achieve promised synergies.
- ·Post-pandemic revenue normalization
- ·Executive leadership uncertainty
- ·Debt servicing concerns
- ·Integration friction from the 2022 merger
Financial
The balance sheet is strained by approximately $2.3 billion in long-term debt. Profitability has swung from massive pandemic-era gains to net losses, and margins are being squeezed by higher interest expenses and lower high-margin diagnostic volumes.
- ·Negative Net Income (TTM)
- ·High Debt-to-Equity ratio (>1.0)
- ·Decreasing gross margins as test mix shifts away from respiratory
- ·P/E ratio currently distorted by earnings volatility
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Continued decline in respiratory testing demand
- ·Interest rate pressure on variable-rate debt
- ·Loss of market share to cheaper generic rapid tests
- ·Execution risk in integrating the legacy Ortho Clinical Diagnostics business
Peer temperature
How direct competitors stack up against QDEL right now.
- HOTDHRDanaher Corp
HOTTER — significantly higher margins and a diversified portfolio that isn't overly reliant on volatile point-of-care testing.
See full analysis → - HOTABTAbbott Laboratories
HOTTER — superior scale and a more resilient medical device segment that offsets fluctuations in their diagnostic division.
See full analysis → - NEUTRALTMOThermo Fisher Scientific
HOTTER — trading at a premium valuation but offers a much more stable 'picks and shovels' play for the entire life sciences sector.
See full analysis →
- QDEL+25.7%
- DHR+4.8%
- ABT+7.5%
- TMO+3.3%
Analyst price target
Consensus average of 4 analysts · median 12.50
Source: StockAnalysis.com · updated 2026-10-14
AI-generated analysis for informational purposes only. Not financial advice.